Drugs / Panblok H7
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03038776 | Jan → Nov 2017 | avian influenza | Vaxine Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02335164 | Jul 2015 → Dec 2017 | avian influenza | Vaxine Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05608005 | Nov 2022 → Feb 2023 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03283319 | Sep → Dec 2017 | influenza | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PanBlok H7 | “PanBlok H7 is a pandemic influenza vaccine produced by PSC in the same way as Flublok but it is directed against H7 rather than seasonal influenza virus strains.” NCT03038776 ↗ |
| Known as | recombinant influenza hemagglutinin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02335164 ↗ |
| Modality | Vaccine | “pandemic avian H5 Influenza Vaccine” NCT02335164 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT02335164 ↗ |